# OnCo record sirolimus (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/sirolimus/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "sirolimus" ;
  schema:name "Sirolimus"@en ;
  schema:alternateName "Rapamycin"@en, "Rapamune" ;
  schema:description "Sirolimus is an anti-rejection tablet taken after an organ transplant. Switching to it from a calcineurin inhibitor roughly halves the number of new skin squamous cell carcinomas in people who have already had one, at the cost of more side effects and a quarter of people stopping it."@en ;
  schema:url <https://onco.cc/drugs/sirolimus/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Sirolimus> ;
  schema:citation <https://doi.org/10.1056/NEJMoa1204166>, <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=RAPAMUNE>, <https://en.wikipedia.org/wiki/Sirolimus> ;
  onco:status "approved" ;
  onco:tag "skin" ;
  onco:modality "Oral mammalian target of rapamycin (mTOR) inhibitor, used as an immunosuppressant" ;
  onco:approval "US 1999: Prophylaxis of organ rejection in kidney transplant recipients" ;
  onco:related <https://onco.cc/drugs/temsirolimus/>, <https://onco.cc/drugs/sirolimus-albumin-bound/>, <https://onco.cc/drugs/cemiplimab/> ;
  onco:cancers <https://onco.cc/cancers/cutaneous-scc/>, <https://onco.cc/cancers/skin-cancer/>, <https://onco.cc/cancers/advanced-cutaneous-scc/> ;
  onco:targets <https://onco.cc/targets/mtor/> ;
  onco:terms <https://onco.cc/terms/skin-cancer-after-organ-transplant/> ;
  onco:trials <https://onco.cc/trials/tumorapa/>, <https://onco.cc/trials/cemiplimab-kidney-transplant-cscc/> .